The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sørensen, P.
Right arrow Articles by Björk, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sørensen, P.
Right arrow Articles by Björk, P.
The Journal of Immunology, 2004, 172: 6803-6809.
Copyright © 2004 by The American Association of Immunologists

Identification of Protein-Protein Interfaces Implicated in CD80-CD28 Costimulatory Signaling

Poul Sørensen1,*, Martin Kussmann2,{dagger}, Anna Rosén*, Keiryn L. Bennett3,{dagger}, Dorthe da Graça Thrige*, Kristina Uvebrant*, Björn Walse*, Peter Roepstorff{dagger} and Per Björk4,*

* Active Biotech Research, Lund, Sweden; and {dagger} Institute for Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark

The B7 ligands CD80 and CD86 on APCs deliver either costimulatory or inhibitory signals to the T cell when interacting with their counter-receptors CD28 and CD152 (CTLA-4) on the T cell surface. Although crucial for lymphocyte regulation, the structural basis of these interactions is still not completely understood. Using multivalent presentation and conditions mimicking clustering, believed to be essential for signaling through these receptors, and by applying a combined differential mass spectrometry and structural mapping approach to these conditions, we were able to identify a putative contact area involving hydrophilic regions on both CD28 and CD80 as well as a putative CD28 oligomerization interface induced by B7 ligation. Analysis of the CD80-CD28 interaction site reveals a well-defined interface structurally distinct from that of CD80 and CD152 and thus provides valuable information for therapeutic intervention targeted at this pathway, suggesting a general approach for other receptors.




This article has been cited by other articles:


Home page
J Biomol ScreenHome page
K. Uvebrant, D. Da Graca Thrige, A. Rosen, M. Akesson, H. Berg, B. Walse, and P. Bjork
Discovery of Selective Small-Molecule CD80 Inhibitors
J Biomol Screen, June 1, 2007; 12(4): 464 - 472.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.